{
    "name": "hydrocodone/acetaminophen",
    "comment": "Rx",
    "other_names": [
        "Vicodin",
        "Lorcet",
        "Hycet",
        "Norco",
        "Lortab Elixir",
        "Anexsia",
        "Vicodin ES",
        "Vicodin HP",
        "Xodol",
        "Zamicet"
    ],
    "classes": [
        "Analgesics",
        "Opioid Combos"
    ],
    "source": "https://reference.medscape.com/drug/vicodin-hydrocodone-acetaminophen-343374",
    "pregnancy": {
        "common": [
            "Prolonged use of opioid analgesics during pregnancy can cause neonatal opioid withdrawal syndrome; there are no available data in pregnant women to inform a drug associated risk for major birth defects and miscarriage; published studies with morphine use during pregnancy have not reported a clear association with opioids and major birth defects",
            "Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth; the onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of drug by newborn; observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Drug is present in breast milk; published lactation studies report variable concentrations of drug in breast milk with administration of immediate-release formulation to nursing mothers in early postpartum period",
            "The developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy; capsules and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition",
            "Monitor infants exposed to drug through breast milk for excess sedation and respiratory depression; withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast- feeding is stopped"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Contains acetaminophen",
                "Hepatotoxicity may occur with acetaminophen doses that exceed 4 g/day; take into account all acetaminophen-containing products the patient is taking, including PRN doses and OTC products",
                "Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplantation or death",
                "New dosage limit allows no more than 325 mg/dosage unit for prescription medications that contain acetaminophen",
                "Healthcare professionals can direct patients to take 1 or 2 tablets, capsules, or other dosage units of a prescription product containing 325 mg of acetaminophen up to 6 times daily (12 dosage units) and still not exceed the maximum daily dose of acetaminophen (ie, 4000 mg/day)"
            ],
            "specific": [
                {
                    "type": "Addiction, abuse, and misuse",
                    "description": [
                        "Long-acting hydrocodone exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death",
                        "Assess each patient’s risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions"
                    ]
                },
                {
                    "type": "Life-threatening respiratory depression",
                    "description": [
                        "Serious, life-threatening, or fatal respiratory depression may occur",
                        "Monitor for respiratory depression, especially during initiation or following a dose increase",
                        "Instruct patients to swallow capsules/tablets whole; crushing, chewing, or dissolving the extended-release dosage forms can cause rapid release and absorption of a potentially fatal dose of hydrocodone"
                    ]
                },
                {
                    "type": "Accidental exposure",
                    "description": [
                        "Accidental consumption of even 1 dose of hydrocodone, especially by children, can result in a fatal overdose of hydrocodone"
                    ]
                },
                {
                    "type": "Neonatal opioid withdrawal syndrome",
                    "description": [
                        "For patients who require opioid therapy while pregnant, be aware that infants may require treatment for neonatal opioid withdrawal syndrome",
                        "Prolonged maternal use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening and requires management according to protocols developed by neonatology experts"
                    ]
                },
                {
                    "type": "Interaction with CNS depressants",
                    "description": [
                        "Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death",
                        "Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate  Limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation",
                        "Coingestion with alcohol may increase hydrocodone plasma levels and result in a potentially fatal overdose (alters release of drug from capsule)"
                    ]
                },
                {
                    "type": "  Interaction with CYP3A4 inhibitors",
                    "description": [
                        "Initiation of CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone from hydrocodone ER"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Significant respiratory depression",
                "Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment",
                "Known or suspected gastrointestinal obstruction, including paralytic ileus",
                "Known hypersensitivity (e.g., anaphylactic reactions, serious skin reactions) to hydrocodone, ibuprofen, or any components of the drug product",
                "Patients known to be hypersensitive to other opioids may exhibit cross-sensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Do not prescribe for acute pain or as needed (prn) pain relief; only for severe chronic pain requiring continuous, around-the-clock opioid analgesia",
                "Hydrocodone is an opioid agonist and a Schedule II controlled substance with a high potential for abuse similar to fentanyl, methadone, morphine, oxycodone, and oxymorphone",
                "Coadministration with other CNS depressants may cause profound sedation, respiratory depression, and death; if coadministration is required, consider dose reduction of 1 or both drugs",
                "Monitor carefully in elderly, cachectic, debilitated patients, and those with chronic pulmonary disease because of increased risk for life-threatening respiratory depression",
                "Monitor patients with head injury or increased ICP for sedation and respiratory depression; avoid use in patients with impaired consciousness or coma susceptible to intracranial effects of CO2 retention",
                "May cause severe hypotension, including orthostatic hypotension and syncope; added risk to individuals whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs such as phenothiazines or other agents which compromise vasomotor tone",
                "Coadministration with CYP3A4 inhibitors may increase hydrocodone systemic exposure and result in toxicity; if co-administration with CYP3A4 necessary, monitor patients closely who are currently taking, or discontinuing, CYP3A4 inhibitors or inducers; evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved",
                "Caution must be used with potentially hazardous activities",
                "Avoid use of mixed agonist/antagonist analgesics (ie, pentazocine, nalbuphine, butorphanol) when taking full opioid agonist analgesics",
                "Profound sedation, respiratory depression, coma, and death may result from concomitant administration with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol); because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate",
                "Cases of adrenal insufficiency reported with opioid use, more often following greater than one month of use; symptoms may include nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure; if adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids; wean patient off of opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers; other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency",
                "May cause spasm of sphincter of Oddi; opioids may cause increases in serum amylase; monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms",
                "Cases of serotonin syndrome, a potentially life-threatening condition, reported with concomitant use of serotonergic drugs; this may occur within the recommended dosage range; the onset of symptoms generally occur within several hours to a few days of concomitant use, but may occur later than that; discontinue therapy immediately if serotonin syndrome is suspected",
                "Use caution in debilitated patients, drug abuse history, elderly patients, G6PD deficiency, head injury, hepatic dysfunction, hypothyroidism, impaired pulmonary function, increased intracranial pressure, toxic psychosis, renal dysfunction",
                "Hydrocodone may obscure diagnosis or clinical symptoms of acute abdominal conditions",
                "Acetaminophen associated with cases of acute liver failure, at times resulting in liver transplantation or death; risk increases in individuals with underlying liver disease, alcohol ingestion, and/or use of more than 1 acetaminophen-containing product (see Black Box Warnings)",
                "Acetaminophen associated with rare, but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash",
                "Caution and awareness are necessary regarding misuse, abuse, or diversion",
                "Constipation may occur; take measures to prevent constipation, such as, administering stool softener and increasing fiber",
                "Chronic alcoholics should limit acetaminophen intake to <2 g/day",
                "Use caution in morbidly obese patients",
                "Use hydrocodone with caution in patients with prostatic hyperplasia and/or urinary stricture",
                "Use caution in patients with seizure disorders"
            ],
            "specific": [
                {
                    "type": "Patient access to naloxone for emergency treatment of opioid overdose",
                    "description": [
                        "Assess potential need for naloxone; consider prescribing for emergency treatment of opioid overdose",
                        "Consult on availability and ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines ",
                        "Educate patients regarding the signs and symptoms of respiratory depression and to call 911 or seek immediate emergency medical help in the event of a known or suspected overdose"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "alvimopan",
            "description": {
                "common": "alvimopan, hydrocodone. receptor binding competition. Contraindicated. Alvimopan is contraindicated in opioid tolerant patients (ie, those who have taken therapeutic doses of opioids for >7 consecutive days immediately prior to taking alvimopan). Patients recently exposed to opioids are expected to be more sensitive to the effects of alvimopan and therefore may experience abdominal pain, nausea and vomiting, and diarrhea. No significant interaction is expected with concurrent use of opioid analgesics and alvimopan in patients who received opioid analgesics for 7 or fewer consecutive days prior to alvimopan."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alfentanil",
            "description": {
                "common": "hydrocodone, alfentanil.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alprazolam",
            "description": {
                "common": "hydrocodone, alprazolam.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amobarbital",
            "description": {
                "common": "hydrocodone, amobarbital.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "arbaclofen",
            "description": {
                "common": "hydrocodone, arbaclofen.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "hydrocodone, aripiprazole.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine",
            "description": {
                "common": "hydrocodone, asenapine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atracurium",
            "description": {
                "common": "hydrocodone, atracurium.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baclofen",
            "description": {
                "common": "hydrocodone, baclofen.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen, hydrocodone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bremelanotide",
            "description": {
                "common": "bremelanotide will decrease the level or effect of hydrocodone by  Other (see comment). Avoid or Use Alternate Drug. Bremelanotide may slow gastric emptying and potentially reduces the rate and extent of absorption of concomitantly administered oral medications. Avoid use when taking any oral drug that is dependent on threshold concentrations for efficacy. Interactions listed are representative examples and do not include all possible clinical examples."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "buprenorphine decreases effects of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Mixed opioid agonists/antagonists and partial opioid agonists may reduce the analgesic effect of hydrocodone and/or precipitate withdrawal symptoms in opioid tolerant patients. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal decreases effects of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Mixed opioid agonists/antagonists and partial opioid agonists may reduce the analgesic effect of hydrocodone and/or precipitate withdrawal symptoms in opioid tolerant patients. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "buprenorphine subdermal implant decreases effects of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Mixed opioid agonists/antagonists and partial opioid agonists may reduce the analgesic effect of hydrocodone and/or precipitate withdrawal symptoms in opioid tolerant patients. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "buprenorphine transdermal decreases effects of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Mixed opioid agonists/antagonists and partial opioid agonists may reduce the analgesic effect of hydrocodone and/or precipitate withdrawal symptoms in opioid tolerant patients. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "buprenorphine, long-acting injection decreases effects of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Mixed opioid agonists/antagonists and partial opioid agonists may reduce the analgesic effect of hydrocodone and/or precipitate withdrawal symptoms in opioid tolerant patients. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buspirone",
            "description": {
                "common": "hydrocodone, buspirone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butabarbital",
            "description": {
                "common": "hydrocodone, butabarbital.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butalbital",
            "description": {
                "common": "hydrocodone, butalbital.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butorphanol",
            "description": {
                "common": "butorphanol decreases effects of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Mixed opioid agonists/antagonists and partial opioid agonists may reduce the analgesic effect of hydrocodone and/or precipitate withdrawal symptoms in opioid tolerant patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium/magnesium/potassium/sodium oxybates",
            "description": {
                "common": "hydrocodone, calcium/magnesium/potassium/sodium oxybates.\nEither increases levels of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cariprazine",
            "description": {
                "common": "hydrocodone, cariprazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carisoprodol",
            "description": {
                "common": "hydrocodone, carisoprodol.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chloral hydrate",
            "description": {
                "common": "hydrocodone, chloral hydrate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "hydrocodone, chlordiazepoxide.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "hydrocodone, chlorpromazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorzoxazone",
            "description": {
                "common": "hydrocodone, chlorzoxazone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "hydrocodone, cisatracurium.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clonazepam",
            "description": {
                "common": "hydrocodone, clonazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clonidine",
            "description": {
                "common": "clonidine, hydrocodone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clorazepate",
            "description": {
                "common": "hydrocodone, clorazepate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "hydrocodone, clozapine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "codeine",
            "description": {
                "common": "hydrocodone, codeine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "hydrocodone, cyclobenzaprine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dantrolene",
            "description": {
                "common": "hydrocodone, dantrolene.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desflurane",
            "description": {
                "common": "hydrocodone, desflurane.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexmedetomidine",
            "description": {
                "common": "hydrocodone, dexmedetomidine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diazepam",
            "description": {
                "common": "hydrocodone, diazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "diazepam intranasal, hydrocodone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxylamine",
            "description": {
                "common": "hydrocodone, doxylamine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estazolam",
            "description": {
                "common": "hydrocodone, estazolam.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eszopiclone",
            "description": {
                "common": "hydrocodone, eszopiclone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethanol",
            "description": {
                "common": "hydrocodone, ethanol.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etomidate",
            "description": {
                "common": "hydrocodone, etomidate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl",
            "description": {
                "common": "hydrocodone, fentanyl.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl intranasal",
            "description": {
                "common": "hydrocodone, fentanyl intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl transdermal",
            "description": {
                "common": "hydrocodone, fentanyl transdermal.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl transmucosal",
            "description": {
                "common": "hydrocodone, fentanyl transmucosal.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "hydrocodone, fluphenazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "flurazepam",
            "description": {
                "common": "hydrocodone, flurazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "haloperidol",
            "description": {
                "common": "hydrocodone, haloperidol.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "hydrocodone, hydromorphone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iloperidone",
            "description": {
                "common": "hydrocodone, iloperidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid increases toxicity of hydrocodone by serotonin levels. Avoid or Use Alternate Drug. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (eg, respiratory depression, coma). Opioids are not recommended for patients taking MAOIs or within 14 days of stopping MAOIs. If urgent opioid treatment needed, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoflurane",
            "description": {
                "common": "hydrocodone, isoflurane.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketamine",
            "description": {
                "common": "hydrocodone, ketamine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levorphanol",
            "description": {
                "common": "hydrocodone, levorphanol.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "linezolid",
            "description": {
                "common": "linezolid increases toxicity of hydrocodone by serotonin levels. Avoid or Use Alternate Drug. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (eg, respiratory depression, coma). Opioids are not recommended for patients taking MAOIs or within 14 days of stopping MAOIs. If urgent opioid treatment needed, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "acetaminophen will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorazepam",
            "description": {
                "common": "hydrocodone, lorazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "loxapine",
            "description": {
                "common": "hydrocodone, loxapine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "hydrocodone, loxapine inhaled.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lurasidone",
            "description": {
                "common": "hydrocodone, lurasidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "meperidine",
            "description": {
                "common": "hydrocodone, meperidine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "meprobamate",
            "description": {
                "common": "hydrocodone, meprobamate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metaxalone",
            "description": {
                "common": "hydrocodone, metaxalone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methadone",
            "description": {
                "common": "hydrocodone, methadone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methocarbamol",
            "description": {
                "common": "hydrocodone, methocarbamol.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methohexital",
            "description": {
                "common": "hydrocodone, methohexital.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylene blue",
            "description": {
                "common": "methylene blue increases toxicity of hydrocodone by serotonin levels. Avoid or Use Alternate Drug. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (eg, respiratory depression, coma). Opioids are not recommended for patients taking MAOIs or within 14 days of stopping MAOIs. If urgent opioid treatment needed, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.  If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "hydrocodone, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "midazolam",
            "description": {
                "common": "hydrocodone, midazolam.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "molindone",
            "description": {
                "common": "hydrocodone, molindone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "morphine",
            "description": {
                "common": "hydrocodone, morphine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nalbuphine",
            "description": {
                "common": "nalbuphine decreases effects of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Mixed opioid agonists/antagonists and partial opioid agonists may reduce the analgesic effect of hydrocodone and/or precipitate withdrawal symptoms in opioid tolerant patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olanzapine",
            "description": {
                "common": "hydrocodone, olanzapine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "hydrocodone and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "hydrocodone, orphenadrine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxazepam",
            "description": {
                "common": "hydrocodone, oxazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxycodone",
            "description": {
                "common": "hydrocodone, oxycodone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "hydrocodone, oxymorphone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod and hydrocodone both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paliperidone",
            "description": {
                "common": "hydrocodone, paliperidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pancuronium",
            "description": {
                "common": "hydrocodone, pancuronium.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentazocine",
            "description": {
                "common": "pentazocine decreases effects of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Mixed opioid agonists/antagonists and partial opioid agonists may reduce the analgesic effect of hydrocodone and/or precipitate withdrawal symptoms in opioid tolerant patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "hydrocodone, pentobarbital.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perphenazine",
            "description": {
                "common": "hydrocodone, perphenazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "acetaminophen and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine increases toxicity of hydrocodone by serotonin levels. Avoid or Use Alternate Drug. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (eg, respiratory depression, coma). Opioids are not recommended for patients taking MAOIs or within 14 days of stopping MAOIs. If urgent opioid treatment needed, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "hydrocodone, phenobarbital.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimavanserin",
            "description": {
                "common": "hydrocodone, pimavanserin.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimozide",
            "description": {
                "common": "hydrocodone, pimozide.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "acetaminophen, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "hydrocodone, primidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "almotriptan",
            "description": {
                "common": "hydrocodone, almotriptan.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alosetron",
            "description": {
                "common": "hydrocodone, alosetron.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "hydrocodone, amitriptyline.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "hydrocodone, amoxapine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphetamine",
            "description": {
                "common": "hydrocodone, amphetamine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "acetaminophen will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "acetaminophen will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "axitinib",
            "description": {
                "common": "acetaminophen increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexanolone",
            "description": {
                "common": "brexanolone, hydrocodone.\nEither increases toxicity of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "acetaminophen, bupivacaine implant.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "bupropion will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "busulfan",
            "description": {
                "common": "acetaminophen increases levels of busulfan by decreasing metabolism. Use Caution/Monitor. Use of acetaminophen prior to (< 72 hours) or concurrently with busulfan may result in decreased clearance of busulfan due to acetaminophen-induced decreases in glutathione levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "celecoxib will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "hydrocodone, citalopram.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "hydrocodone, clobazam. Other (see comment). Use Caution/Monitor. \nComment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "hydrocodone, clomipramine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone topical",
            "description": {
                "common": "acetaminophen increases toxicity of dapsone topical by altering metabolism. Modify Therapy/Monitor Closely. May induce methemoglobinemia ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "hydrocodone and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "darifenacin will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "hydrocodone, desipramine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "desvenlafaxine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "hydrocodone, dextroamphetamine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and hydrocodone both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and hydrocodone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "diphenhydramine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "hydrocodone, doxepin.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "duloxetine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix decreases levels of hydrocodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eletriptan",
            "description": {
                "common": "hydrocodone, eletriptan.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eltrombopag",
            "description": {
                "common": "eltrombopag increases levels of acetaminophen by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib, hydrocodone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "hydrocodone, escitalopram.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, hydrocodone.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable solution",
            "description": {
                "common": "exenatide injectable solution will decrease the level or effect of acetaminophen by  unspecified interaction mechanism. Use Caution/Monitor. To avoid potential interaction, give acetaminophen at least 1 hour before or 4 hours after exenatide injection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable suspension",
            "description": {
                "common": "exenatide injectable suspension will decrease the level or effect of acetaminophen by  unspecified interaction mechanism. Use Caution/Monitor. To avoid potential interaction, give acetaminophen at least 1 hour before or 4 hours after exenatide injection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "acetaminophen will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or moderate CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "hydrocodone, flibanserin.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "hydrocodone, fluoxetine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib decreases levels of acetaminophen by decreasing hepatic clearance. Modify Therapy/Monitor Closely. In vitro, imatinib was found to inhibit acetaminophen O-glucuronidation (Ki value of 58.5 micro-M) at therapeutic levels; avoid chronic acetaminophen therapy with imatinib; if occasional acetaminophen administered, do not exceed 1300 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine and hydrocodone both increase  serotonin levels. Use Caution/Monitor. If concomitant use warranted, carfully observe patient, particularly during treatment initiation and dose adjustment"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "hydrocodone, frovatriptan.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin",
            "description": {
                "common": "gabapentin, hydrocodone.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "gabapentin enacarbil, hydrocodone.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "hydrocodone and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "hydrocodone, imipramine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "acetaminophen will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "acetaminophen increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, hydrocodone.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "acetaminophen will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of acetaminophen by  unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of hydrocodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "hydrocodone, levomilnacipran.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "hydrocodone, lisdexamfetamine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lixisenatide (DSC)",
            "description": {
                "common": "lixisenatide (DSC) will decrease the level or effect of acetaminophen by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. GLP1 agonists delay gastric emptying, which may affect absorption of concomitantly administered oral medications. No effects on acetaminophen Cmax and Tmax were observed when acetaminophen was administered 1 hr before lixisenatide. When administered 1 or 4 hr after lixisenatide, acetaminophen Cmax was decreased by 29% and 31% respectively and median Tmax was delayed by 2 and 1.75 hr, respectively."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "acetaminophen increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "hydrocodone, lorcaserin.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "lumefantrine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, hydrocodone.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "hydrocodone, maprotiline.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "marijuana",
            "description": {
                "common": "marijuana will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "hydrocodone, methamphetamine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate",
            "description": {
                "common": "hydrocodone, methylphenidate.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "acetaminophen will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.  Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mipomersen",
            "description": {
                "common": "mipomersen, acetaminophen.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Both drugs have potential to increase hepatic enzymes; monitor LFTs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "milnacipran",
            "description": {
                "common": "hydrocodone, milnacipran.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "hydrocodone, mirtazapine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naratriptan",
            "description": {
                "common": "hydrocodone, naratriptan.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nilotinib will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Careful monitoring of hydrocodone therapeutic and adverse effects (including potentially fatal respiratory depression) recommended when coadministered. Reduce hydrocodone dose if necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "hydrocodone, nortriptyline.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "oliceridine, hydrocodone.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "parecoxib will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegvisomant",
            "description": {
                "common": "hydrocodone will decrease the level or effect of pegvisomant by  unknown mechanism. Use Caution/Monitor. Prescribing information describes higher pegvisomant doses are required to control insulinlike growth factor levels when coadministered with opioids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pregabalin",
            "description": {
                "common": "pregabalin, hydrocodone.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "propafenone will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "hydrocodone, protriptyline.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinacrine",
            "description": {
                "common": "quinacrine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranolazine",
            "description": {
                "common": "ranolazine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "remimazolam",
            "description": {
                "common": "remimazolam, hydrocodone.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rizatriptan",
            "description": {
                "common": "hydrocodone, rizatriptan.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "safinamide",
            "description": {
                "common": "hydrocodone, safinamide.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. May also enhance CNS depressant effect of hydrocodone"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, hydrocodone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sumatriptan",
            "description": {
                "common": "hydrocodone, sumatriptan.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sumatriptan intranasal",
            "description": {
                "common": "hydrocodone, sumatriptan intranasal.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracaine",
            "description": {
                "common": "tetracaine, acetaminophen. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "thioridazine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "acetaminophen will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "hydrocodone, trazodone.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "hydrocodone, trimipramine.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "venlafaxine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "acetaminophen increases effects of warfarin by anticoagulation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "hydrocodone, zolmitriptan.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "albiglutide",
            "description": {
                "common": "albiglutide decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "acetaminophen increases effects of antithrombin alfa by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "acetaminophen increases effects of antithrombin III by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "argatroban",
            "description": {
                "common": "acetaminophen increases effects of argatroban by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bemiparin",
            "description": {
                "common": "acetaminophen increases effects of bemiparin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "acetaminophen increases effects of bivalirudin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of acetaminophen by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonazepam",
            "description": {
                "common": "clonazepam decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colestipol",
            "description": {
                "common": "colestipol decreases levels of acetaminophen by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dalteparin",
            "description": {
                "common": "acetaminophen increases effects of dalteparin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diazepam",
            "description": {
                "common": "diazepam decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "disulfiram",
            "description": {
                "common": "disulfiram will increase the level or effect of acetaminophen by  affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "acetaminophen increases effects of enoxaparin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol will decrease the level or effect of acetaminophen by  affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "ethosuximide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felbamate",
            "description": {
                "common": "felbamate decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "acetaminophen increases effects of fondaparinux by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "green tea",
            "description": {
                "common": "green tea increases effects of acetaminophen by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical, due to caffeine content)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "heparin",
            "description": {
                "common": "acetaminophen increases effects of heparin by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid increases toxicity of acetaminophen by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lacosamide",
            "description": {
                "common": "lacosamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lamotrigine",
            "description": {
                "common": "lamotrigine decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levetiracetam",
            "description": {
                "common": "levetiracetam decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "liraglutide",
            "description": {
                "common": "liraglutide decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lorazepam",
            "description": {
                "common": "lorazepam decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methsuximide",
            "description": {
                "common": "methsuximide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metoclopramide",
            "description": {
                "common": "metoclopramide increases levels of acetaminophen by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metronidazole",
            "description": {
                "common": "metronidazole will increase the level or effect of acetaminophen by  affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxybutynin",
            "description": {
                "common": "oxybutynin decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxybutynin topical",
            "description": {
                "common": "oxybutynin topical decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxybutynin transdermal",
            "description": {
                "common": "oxybutynin transdermal decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenindione",
            "description": {
                "common": "acetaminophen increases effects of phenindione by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protamine",
            "description": {
                "common": "acetaminophen increases effects of protamine by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rufinamide",
            "description": {
                "common": "rufinamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "acetaminophen will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "acetaminophen will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tiagabine",
            "description": {
                "common": "tiagabine decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "valproic acid",
            "description": {
                "common": "valproic acid decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ziconotide",
            "description": {
                "common": "ziconotide, hydrocodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Additive decreased GI motility. Additive analgesia. Ziconotide does NOT potentiate opioid induced respiratory depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zonisamide",
            "description": {
                "common": "zonisamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism increase levels of hepatotoxic metabolites."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Biliary tract spasm",
            "percent": null
        },
        {
            "name": "Hallucinations",
            "percent": null
        },
        {
            "name": "Circulatory collapse",
            "percent": null
        },
        {
            "name": "Histamine release",
            "percent": null
        },
        {
            "name": "Physical and psychological dependence with prolonged use",
            "percent": null
        },
        {
            "name": "Urinary tract spasm",
            "percent": null
        },
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "Cardiac arrest",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Decreased urination",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Drowsiness",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Coma",
            "percent": null
        },
        {
            "name": "Dysphoria",
            "percent": null
        },
        {
            "name": "Euphoria",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "Lightheadedness",
            "percent": null
        },
        {
            "name": "Mood changes",
            "percent": null
        },
        {
            "name": "Stupor",
            "percent": null
        },
        {
            "name": "Mental clouding",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Sedation",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Weakness",
            "percent": null
        },
        {
            "name": "Peptic ulcer",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Hemolytic anemia",
            "percent": null
        },
        {
            "name": "Hepatic necrosis",
            "percent": null
        },
        {
            "name": "Respiratory depression",
            "percent": null
        }
    ]
}